The most commonly reported side effects of erenumab include accidental exposure to product, device difficult to use, and wrong technique in product usage process, based on 54,268 FDA adverse event reports from 2009 to 2025. 8.1% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for erenumab.
These are voluntary reports and do not establish that erenumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside erenumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
70.3% of erenumab adverse event reports involve female patients and 11.5% involve male patients. The largest age group is adult at 82%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking erenumab when the adverse event was reported.
Showing 15 of 226 indications
Erenumab is sold under the brand name Aimovig.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.